CN108815130A - A kind of Cefpodoxime Proxetil tablet and its production technology - Google Patents
A kind of Cefpodoxime Proxetil tablet and its production technology Download PDFInfo
- Publication number
- CN108815130A CN108815130A CN201810978652.0A CN201810978652A CN108815130A CN 108815130 A CN108815130 A CN 108815130A CN 201810978652 A CN201810978652 A CN 201810978652A CN 108815130 A CN108815130 A CN 108815130A
- Authority
- CN
- China
- Prior art keywords
- parts
- cefpodoxime proxetil
- organic solvent
- filler
- disintegrating agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Abstract
The invention discloses a kind of Cefpodoxime Proxetil tablets, including below according to the raw material of parts by weight：30-50 parts of Cefpodoxime Proxetil crude product, 10-20 parts of organic solvent A, 5-15 parts of organic weak base salting liquid, 10-20 parts of active carbon, 5-10 parts of 1- iodine ethylisopropyl base carbonic ester, 6-12 parts of organic solvent B, 2-8 parts of filler, 2-6 parts of disintegrating agent, 6-12 parts of binder aqueous solution, Utech
Description
Technical field
The present invention relates to technical field of medicine, specifically a kind of Cefpodoxime Proxetil tablet and its production technology.
Background technique
Cefpodoxime Proxetil advantage of powerful antibacterial action, long half time by its wide spectrum, is widely applied on people's medicine
In respiratory tract, the urinary tract, gynecological infections disease and otitis media suppurative etc., dosage form include coating tablet, dispersible tablet, capsule,
Particle, dry suspensoid agent.Cefpodoxime Proxetil is to take orally broad-spectrum cephalosporin the 3rd generation, is hydrolyzed into Cefpodoxime in intestinal wall after oral and passes through
Intestinal absorption.Cefpodoxime has wide spectrum and powerful antibacterial action, long half time, is widely used in respiratory tract, the urinary tract, woman's production
The treatment of section's infectious diseases and otitis media suppurative etc..And prepare auxiliary material used in the method for Cefpodoxime Proxetil tablet mostly now
It is more, and preparation process is complicated, the tablet yield rate of device therefor preparation is lower, is unfavorable for industrialized production.
Summary of the invention
The purpose of the present invention is to provide a kind of Cefpodoxime Proxetil tablet and its production technologies, to solve above-mentioned background technique
The problem of middle proposition.
To achieve the above object, the present invention provides the following technical solutions：
A kind of Cefpodoxime Proxetil tablet, including below according to the raw material of parts by weight：30-50 parts of Cefpodoxime Proxetil crude product has
A10-20 parts of solvent, 5-15 parts of organic weak base salting liquid, 10-20 parts of active carbon, 1- iodine ethylisopropyl base carbonic ester 5-10
Part, 6-12 parts of organic solvent B, 2-8 parts of filler, 2-6 parts of disintegrating agent, 6-12 parts of binder aqueous solution, EPO3-7
Part, 1-7 parts of corrigent, 2-9 parts of sodium alginate, 1-5 parts of isomalt.
As a further solution of the present invention：Including below according to the raw material of parts by weight：Cefpodoxime Proxetil crude product 35-45
Part, 12-18 parts of organic solvent A, 8-12 parts of organic weak base salting liquid, 13-17 parts of active carbon, 1- iodine ethylisopropyl base carbonic ester
7-9 parts, 8-10 parts of organic solvent B, 4-6 parts of filler, 3-5 parts of disintegrating agent, 8-10 parts of binder aqueous solution,EPO4-
6 parts, 2-6 parts of corrigent, 3-7 parts of sodium alginate, 2-4 parts of isomalt.
As further scheme of the invention：Including below according to the raw material of parts by weight：40 parts of Cefpodoxime Proxetil crude product,
15 parts of organic solvent A, 10 parts of organic weak base salting liquid, 15 parts of active carbon, 8 parts of 1- iodine ethylisopropyl base carbonic ester, You Jirong
B9 parts of agent, 5 parts of filler, 4 parts of disintegrating agent, 9 parts of binder aqueous solution,EPO5 parts, 4 parts of corrigent, sodium alginate 5
Part, 2 parts of isomalt.
As further scheme of the invention：The organic solvent A is the mixing of methanol, chloroform and tetrahydrofuran
Object, organic solvent B are n,N-dimethylacetamide.
As further scheme of the invention：The filler is microcrystalline cellulose, Lactis Anhydrous, maltodextrin
One of, the disintegrating agent be sodium carboxymethyl starch, the corrigent be artificial chicken essence, Artificial Beef essence,
One of yeast powder.
A kind of production technology of the Cefpodoxime Proxetil tablet, includes the following steps：
The preparation of S1 Cefpodoxime Proxetil：Cefpodoxime Proxetil crude product is dissolved in organic solvent A, it is molten that organic weak base salt is added
Liquid is stirred to react, and cefpoxime proxetil is obtained after hydrolysis；Then plus activated carbon adsorption, filtering are eventually adding 1- iodine ethylisopropyl base carbon
Acid esters reacts under the conditions of existing for the organic solvent B, obtains Cefpodoxime Proxetil；
The screening of S2 material：Cefpodoxime Proxetil, filler, disintegrating agent are crossed into 80 meshes respectively, it is spare；
S3：Cefpodoxime Proxetil, filler, disintegrating agent after taking sieving in proportion are uniformly mixed, with sodium alginate, different malt
The pure and mild binder aqueous solution softwood of ketose crosses the granulation of 40 meshes, dry under the conditions of 40 DEG C ± 5 DEG C, crosses 40 mesh and 65 meshes
Whole grain removes coarse granule and fine powder to get particle；
S4 coating：Particle obtained by step S3 is usedEPO carries out fluidized bed coating, and it is whole then to cross 40-60 mesh
Grain removes coarse granule and fine powder to get particle after coating；
S5：It particle will be uniformly mixed with corrigent after coating obtained by step S4, then tabletting is to get to Cefpodoxime Proxetil medicine
Piece.
As further scheme of the invention：The water-soluble weight percent concentration of described adhesive is 3%~8%.
Compared with prior art, the beneficial effects of the invention are as follows：Cefpodoxime Proxetil tablet of the invention is straight using its crude product
Preparation is connect, Cefpodoxime Proxetil tablet is avoided to waste because of crude product, while many unnecessary preparation steps can be reduced, and be
Keep the pill of main ingredient ingredient firmer, further does consolidation coating, the Cefpodoxime Proxetil purity of synthesis is higher, improve clinic
The quality of preparation has ensured the safety of medication；This method simple process, easy to operate, at low cost, yield rate is higher, is suitble to
In large-scale production.
Specific embodiment
The technical solution of the patent is explained in further detail With reference to embodiment.
Embodiment one：
A kind of Cefpodoxime Proxetil tablet, including below according to the raw material of parts by weight：30 parts of Cefpodoxime Proxetil crude product, You Jirong
A10 parts of agent, 5 parts of organic weak base salting liquid, 10 parts of active carbon, 5 parts of 1- iodine ethylisopropyl base carbonic ester, 6 parts of organic solvent B,
2 parts of filler, 2 parts of disintegrating agent, 6 parts of binder aqueous solution,EPO3 parts, 1 part of corrigent, 2 parts of sodium alginate, different wheat
1 part of bud ketose alcohol.
The organic solvent A is the mixture of methanol, chloroform and tetrahydrofuran, weight ratio 1:2:4, You Jirong
Agent B is n,N-dimethylacetamide.
The filler is microcrystalline cellulose, and the disintegrating agent is sodium carboxymethyl starch, and the corrigent is behaved
Make chicken essence.
A kind of production technology of the Cefpodoxime Proxetil tablet, includes the following steps：
The preparation of S1 Cefpodoxime Proxetil：Cefpodoxime Proxetil crude product is dissolved in organic solvent A, it is molten that organic weak base salt is added
Liquid is stirred to react, and cefpoxime proxetil is obtained after hydrolysis；Then plus activated carbon adsorption, filtering are eventually adding 1- iodine ethylisopropyl base carbon
Acid esters reacts under the conditions of existing for the organic solvent B, obtains Cefpodoxime Proxetil；
The screening of S2 material：Cefpodoxime Proxetil, filler, disintegrating agent are crossed into 80 meshes respectively, it is spare；
S3：Cefpodoxime Proxetil, filler, disintegrating agent after taking sieving in proportion are uniformly mixed, with sodium alginate, different malt
The pure and mild binder aqueous solution softwood of ketose crosses the granulation of 40 meshes, dry under the conditions of 45 DEG C, crosses 65 mesh sieves, removes thick
Particle and fine powder are to get particle；
S4 coating：Particle obtained by step S3 is usedEPO carries out fluidized bed coating, then crosses 60 mesh sieves, removes
Go coarse granule and fine powder to get particle after coating；
S5：It particle will be uniformly mixed with corrigent after coating obtained by step S4, then tabletting is to get to Cefpodoxime Proxetil medicine
Piece.
The water-soluble weight percent concentration of described adhesive is 3%.
Embodiment two：
A kind of Cefpodoxime Proxetil tablet, including below according to the raw material of parts by weight：35 parts of Cefpodoxime Proxetil crude product, You Jirong
A12 parts of agent, 8 parts of organic weak base salting liquid, 13 parts of active carbon, 7 parts of 1- iodine ethylisopropyl base carbonic ester, 8 parts of organic solvent B,
4 parts of filler, 3 parts of disintegrating agent, 8 parts of binder aqueous solution,EPO4 parts, 2 parts of corrigent, 3 parts of sodium alginate, different wheat
2 parts of bud ketose alcohol.
The organic solvent A is the mixture of methanol, chloroform and tetrahydrofuran, weight ratio 1:1:4, You Jirong
Agent B is n,N-dimethylacetamide.
The filler is Lactis Anhydrous, and the disintegrating agent is sodium carboxymethyl starch, and the corrigent is artificial
Beef flavor.
A kind of production technology of the Cefpodoxime Proxetil tablet, includes the following steps：
The preparation of S1 Cefpodoxime Proxetil：Cefpodoxime Proxetil crude product is dissolved in organic solvent A, it is molten that organic weak base salt is added
Liquid is stirred to react, and cefpoxime proxetil is obtained after hydrolysis；Then plus activated carbon adsorption, filtering are eventually adding 1- iodine ethylisopropyl base carbon
Acid esters reacts under the conditions of existing for the organic solvent B, obtains Cefpodoxime Proxetil；
The screening of S2 material：Cefpodoxime Proxetil, filler, disintegrating agent are crossed into 80 meshes respectively, it is spare；
S3：Cefpodoxime Proxetil, filler, disintegrating agent after taking sieving in proportion are uniformly mixed, with sodium alginate, different malt
The pure and mild binder aqueous solution softwood of ketose crosses the granulation of 40 meshes, dry under the conditions of 35 DEG C, crosses 40 mesh sieves, removes thick
Particle and fine powder are to get particle；
S4 coating：Particle obtained by step S3 is usedEPO carries out fluidized bed coating, then crosses 40 mesh sieves, removes
Go coarse granule and fine powder to get particle after coating；
S5：It particle will be uniformly mixed with corrigent after coating obtained by step S4, then tabletting is to get to Cefpodoxime Proxetil medicine
Piece.
The water-soluble weight percent concentration of described adhesive is 4%.
Embodiment three：
A kind of Cefpodoxime Proxetil tablet, including below according to the raw material of parts by weight：40 parts of Cefpodoxime Proxetil crude product, You Jirong
A15 parts of agent, 10 parts of organic weak base salting liquid, 15 parts of active carbon, 8 parts of 1- iodine ethylisopropyl base carbonic ester, 9 parts of organic solvent B,
5 parts of filler, 4 parts of disintegrating agent, 9 parts of binder aqueous solution,EPO5 parts, 4 parts of corrigent, 5 parts of sodium alginate, different wheat
3 parts of bud ketose alcohol.
The organic solvent A is the mixture of methanol, chloroform and tetrahydrofuran, weight ratio 1:1:4, You Jirong
Agent B is n,N-dimethylacetamide.
The filler is maltodextrin, and the disintegrating agent is sodium carboxymethyl starch, and the corrigent is ferment
Female powder.
A kind of production technology of the Cefpodoxime Proxetil tablet, includes the following steps：
The preparation of S1 Cefpodoxime Proxetil：Cefpodoxime Proxetil crude product is dissolved in organic solvent A, it is molten that organic weak base salt is added
Liquid is stirred to react, and cefpoxime proxetil is obtained after hydrolysis；Then plus activated carbon adsorption, filtering are eventually adding 1- iodine ethylisopropyl base carbon
Acid esters reacts under the conditions of existing for the organic solvent B, obtains Cefpodoxime Proxetil；
The screening of S2 material：Cefpodoxime Proxetil, filler, disintegrating agent are crossed into 80 meshes respectively, it is spare；
S3：Cefpodoxime Proxetil, filler, disintegrating agent after taking sieving in proportion are uniformly mixed, with sodium alginate, different malt
The pure and mild binder aqueous solution softwood of ketose crosses the granulation of 40 meshes, dry under the conditions of 45 DEG C, crosses 40 mesh and 65 mesh sieves,
Coarse granule and fine powder are removed to get particle；
S4 coating：Particle obtained by step S3 is usedEPO carries out fluidized bed coating, then crosses 50 mesh sieves, removes
Go coarse granule and fine powder to get particle after coating；
S5：It particle will be uniformly mixed with corrigent after coating obtained by step S4, then tabletting is to get to Cefpodoxime Proxetil medicine
Piece.
The water-soluble weight percent concentration of described adhesive is 5%.
Example IV：
A kind of Cefpodoxime Proxetil tablet, including below according to the raw material of parts by weight：45 parts of Cefpodoxime Proxetil crude product, You Jirong
A18 parts of agent, 12 parts of organic weak base salting liquid, 17 parts of active carbon, 9 parts of 1- iodine ethylisopropyl base carbonic ester, organic solvent B 10
Part, 6 parts of filler, 5 parts of disintegrating agent, 10 parts of binder aqueous solution,EPO6 parts, 6 parts of corrigent, 7 parts of sodium alginate,
4 parts of isomalt.
The organic solvent A is the mixture of methanol, chloroform and tetrahydrofuran, weight ratio 1:3:4, You Jirong
Agent B is n,N-dimethylacetamide.
The filler is maltodextrin, and the disintegrating agent is sodium carboxymethyl starch, and the corrigent is ferment
Female powder.
A kind of production technology of the Cefpodoxime Proxetil tablet, includes the following steps：
The preparation of S1 Cefpodoxime Proxetil：Cefpodoxime Proxetil crude product is dissolved in organic solvent A, it is molten that organic weak base salt is added
Liquid is stirred to react, and cefpoxime proxetil is obtained after hydrolysis；Then plus activated carbon adsorption, filtering are eventually adding 1- iodine ethylisopropyl base carbon
Acid esters reacts under the conditions of existing for the organic solvent B, obtains Cefpodoxime Proxetil；
The screening of S2 material：Cefpodoxime Proxetil, filler, disintegrating agent are crossed into 80 meshes respectively, it is spare；
S3：Cefpodoxime Proxetil, filler, disintegrating agent after taking sieving in proportion are uniformly mixed, with sodium alginate, different malt
The pure and mild binder aqueous solution softwood of ketose crosses the granulation of 40 meshes, dry under the conditions of 45 DEG C, crosses 40 mesh and 65 mesh sieves,
Coarse granule and fine powder are removed to get particle；
S4 coating：Particle obtained by step S3 is usedEPO carries out fluidized bed coating, then crosses 60 mesh sieves, removes
Go coarse granule and fine powder to get particle after coating；
S5：It particle will be uniformly mixed with corrigent after coating obtained by step S4, then tabletting is to get to Cefpodoxime Proxetil medicine
Piece.
The water-soluble weight percent concentration of described adhesive is 6%.
Embodiment five：
A kind of Cefpodoxime Proxetil tablet, including below according to the raw material of parts by weight：50 parts of Cefpodoxime Proxetil crude product, You Jirong
A20 parts of agent, 15 parts of organic weak base salting liquid, 20 parts of active carbon, 10 parts of 1- iodine ethylisopropyl base carbonic ester, organic solvent B 12
Part, 8 parts of filler, 6 parts of disintegrating agent, 12 parts of binder aqueous solution,EPO7 parts, 7 parts of corrigent, 9 parts of sodium alginate,
5 parts of isomalt.
The organic solvent A is the mixture of methanol, chloroform and tetrahydrofuran, weight ratio 2:3:4, You Jirong
Agent B is n,N-dimethylacetamide.
The filler is microcrystalline cellulose, and the disintegrating agent is sodium carboxymethyl starch, and the corrigent is ferment
Female powder.
A kind of production technology of the Cefpodoxime Proxetil tablet, includes the following steps：
The preparation of S1 Cefpodoxime Proxetil：Cefpodoxime Proxetil crude product is dissolved in organic solvent A, it is molten that organic weak base salt is added
Liquid is stirred to react, and cefpoxime proxetil is obtained after hydrolysis；Then plus activated carbon adsorption, filtering are eventually adding 1- iodine ethylisopropyl base carbon
Acid esters reacts under the conditions of existing for the organic solvent B, obtains Cefpodoxime Proxetil；
The screening of S2 material：Cefpodoxime Proxetil, filler, disintegrating agent are crossed into 80 meshes respectively, it is spare；
S3：Cefpodoxime Proxetil, filler, disintegrating agent after taking sieving in proportion are uniformly mixed, with sodium alginate, different malt
The pure and mild binder aqueous solution softwood of ketose crosses the granulation of 40 meshes, dry under the conditions of 40 DEG C ± 5 DEG C, crosses 60 mesh sieves, removes
Go coarse granule and fine powder to get particle；
S4 coating：Particle obtained by step S3 is usedEPO carries out fluidized bed coating, then crosses 60 mesh sieves, removes
Go coarse granule and fine powder to get particle after coating；
S5：It particle will be uniformly mixed with corrigent after coating obtained by step S4, then tabletting is to get to Cefpodoxime Proxetil medicine
Piece.
The water-soluble weight percent concentration of described adhesive is 8%.
Comparative example 1
Compared with Example 3, isomalt is free of, other are same as Example 3.
Comparative example 2
Compared with Example 3, sodium alginate is free of, other are same as Example 3.
Comparative example 3
Compared with Example 3, isomalt, sodium alginate are free of, other are same as Example 3.
Example 1, comparative example 2, comparative example 3 and reality are compared by the measuring instrument TBH 30 of Erweka company after measured
Apply the fracture strength of Cefpodoxime Proxetil tablet prepared by example three, such as following table：
By contrast under the identical volume of Cefpodoxime Proxetil medicine prepared by example 1, comparative example 2, comparative example 3 and embodiment three
Dissolution time
According to upper table can be seen that embodiment three prepared by Cefpodoxime Proxetil tablet hardness it is higher and avoid fragile
It splits, and then yield rate is higher, is suitable for large-scale production, while the time dissolved is shorter and improve the performance of drug effect.
It is obvious to a person skilled in the art that invention is not limited to the details of the above exemplary embodiments, Er Qie
In the case where without departing substantially from spirit or essential attributes of the invention, the present invention can be realized in other specific forms.Therefore, no matter
From the point of view of which point, the present embodiments are to be considered as illustrative and not restrictive, and the scope of the present invention is by appended power
Benefit requires rather than above description limits, it is intended that all by what is fallen within the meaning and scope of the equivalent elements of the claims
Variation is included within the present invention.
In addition, it should be understood that although this specification is described in terms of embodiments, but not each embodiment is only wrapped
Containing an independent technical solution, this description of the specification is merely for the sake of clarity, and those skilled in the art should
It considers the specification as a whole, the technical solutions in the various embodiments may also be suitably combined, forms those skilled in the art
The other embodiments being understood that.
Claims (7)
1. a kind of Cefpodoxime Proxetil tablet, which is characterized in that including below according to the raw material of parts by weight：Cefpodoxime Proxetil crude product
30-50 parts, 10-20 parts of organic solvent A, 5-15 parts of organic weak base salting liquid, 10-20 parts of active carbon, 1- iodine ethylisopropyl base
5-10 parts of carbonic ester, 6-12 parts of organic solvent B, 2-8 parts of filler, 2-6 parts of disintegrating agent, 6-12 parts of binder aqueous solution,EPO3-7 parts, 1-7 parts of corrigent, 2-9 parts of sodium alginate, 1-5 parts of isomalt.
2. Cefpodoxime Proxetil tablet according to claim 1, which is characterized in that including below according to the raw material of parts by weight：
35-45 parts of Cefpodoxime Proxetil crude product, 12-18 parts of organic solvent A, 8-12 parts of organic weak base salting liquid, 13-17 parts of active carbon,
7-9 parts of 1- iodine ethylisopropyl base carbonic ester, 8-10 parts of organic solvent B, 4-6 parts of filler, 3-5 parts of disintegrating agent, adhesive are water-soluble
8-10 parts of liquid,EPO4-6 parts, 2-6 parts of corrigent, 3-7 parts of sodium alginate, 2-4 parts of isomalt.
3. Cefpodoxime Proxetil tablet according to claim 1, which is characterized in that including below according to the raw material of parts by weight：
40 parts of Cefpodoxime Proxetil crude product, 15 parts of organic solvent A, 10 parts of organic weak base salting liquid, 15 parts of active carbon, 1- iodine ethylisopropyl
8 parts of base carbonic ester, 9 parts of organic solvent B, 5 parts of filler, 4 parts of disintegrating agent, 9 parts of binder aqueous solution,EPO5 parts, rectify
4 parts of taste agent, 5 parts of sodium alginate, 3 parts of isomalt.
4. Cefpodoxime Proxetil tablet according to claim 1, which is characterized in that the organic solvent A is methanol, three chloromethanes
The mixture of alkane and tetrahydrofuran, organic solvent B are n,N-dimethylacetamide.
5. Cefpodoxime Proxetil tablet according to claim 1, which is characterized in that the filler be microcrystalline cellulose,
One of Lactis Anhydrous, maltodextrin, the disintegrating agent are sodium carboxymethyl starch, and the corrigent is synthetic chicken
One of essence, Artificial Beef essence, yeast powder.
6. a kind of production technology of Cefpodoxime Proxetil tablet a method as claimed in any one of claims 1 to 5, which is characterized in that including following
Step：
The preparation of S1 Cefpodoxime Proxetil：Cefpodoxime Proxetil crude product is dissolved in organic solvent A, organic weak base salting liquid is added,
It is stirred to react, cefpoxime proxetil is obtained after hydrolysis；Then plus activated carbon adsorption, filtering are eventually adding 1- iodine ethylisopropyl base carbonic acid
Ester reacts under the conditions of existing for the organic solvent B, obtains Cefpodoxime Proxetil；
The screening of S2 material：Cefpodoxime Proxetil, filler, disintegrating agent are crossed into 80 meshes respectively, it is spare；
S3：Cefpodoxime Proxetil, filler, disintegrating agent after taking sieving in proportion are uniformly mixed, with sodium alginate, isomaltoketose
Pure and mild binder aqueous solution softwood crosses the granulation of 40 meshes, dry under the conditions of 40 DEG C ± 5 DEG C, crosses 40 mesh and 65 mesh sieves,
Coarse granule and fine powder are removed to get particle；
S4 coating：Particle obtained by step S3 is usedEPO carries out fluidized bed coating, then crosses 40-60 mesh sieve, removes
Go coarse granule and fine powder to get particle after coating；
S5：It particle will be uniformly mixed with corrigent after coating obtained by step S4, then tabletting is to get to Cefpodoxime Proxetil tablet.
7. the production technology of Cefpodoxime Proxetil tablet according to claim 6, which is characterized in that described adhesive is water-soluble heavy
Measuring percent concentration is 3%~8%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810978652.0A CN108815130A (en) | 2018-08-27 | 2018-08-27 | A kind of Cefpodoxime Proxetil tablet and its production technology |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810978652.0A CN108815130A (en) | 2018-08-27 | 2018-08-27 | A kind of Cefpodoxime Proxetil tablet and its production technology |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108815130A true CN108815130A (en) | 2018-11-16 |
Family
ID=64150686
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810978652.0A Pending CN108815130A (en) | 2018-08-27 | 2018-08-27 | A kind of Cefpodoxime Proxetil tablet and its production technology |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108815130A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113072567A (en) * | 2021-03-26 | 2021-07-06 | 海南海灵化学制药有限公司 | Synthesis process of latamoxef sodium |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001037816A2 (en) * | 1999-11-23 | 2001-05-31 | Biochemie Gesellschaft M.B.H. | Coating of tablet cores |
| CN101550148A (en) * | 2009-05-07 | 2009-10-07 | 郑仙锋 | Cefpodoxime proxetil compound and preparation method thereof |
| CN101965180A (en) * | 2008-03-03 | 2011-02-02 | 曼海姆/奥克森福特旭德楚克股份公司 | Mixture for producing rapidly disintegrating tablets |
| WO2012026907A2 (en) * | 2010-08-25 | 2012-03-01 | Mahmut Bilgic | Cefpodoxime proxetil formulations |
| WO2014123500A1 (en) * | 2013-02-11 | 2014-08-14 | Bilgiç Mahmut | Pharmaceutical formulations comprising cefpodoxime proxetil and clavulanic acid |
| CN105963269A (en) * | 2016-06-27 | 2016-09-28 | 齐鲁动物保健品有限公司 | Cefpodoxime proxetil flavored chewable tablet and preparation method thereof |
-
2018
- 2018-08-27 CN CN201810978652.0A patent/CN108815130A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001037816A2 (en) * | 1999-11-23 | 2001-05-31 | Biochemie Gesellschaft M.B.H. | Coating of tablet cores |
| CN101965180A (en) * | 2008-03-03 | 2011-02-02 | 曼海姆/奥克森福特旭德楚克股份公司 | Mixture for producing rapidly disintegrating tablets |
| CN101550148A (en) * | 2009-05-07 | 2009-10-07 | 郑仙锋 | Cefpodoxime proxetil compound and preparation method thereof |
| WO2012026907A2 (en) * | 2010-08-25 | 2012-03-01 | Mahmut Bilgic | Cefpodoxime proxetil formulations |
| WO2014123500A1 (en) * | 2013-02-11 | 2014-08-14 | Bilgiç Mahmut | Pharmaceutical formulations comprising cefpodoxime proxetil and clavulanic acid |
| CN105963269A (en) * | 2016-06-27 | 2016-09-28 | 齐鲁动物保健品有限公司 | Cefpodoxime proxetil flavored chewable tablet and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 侯秀英等: "《新编现代实用药剂学》", 31 July 2015, 西安交通大学出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113072567A (en) * | 2021-03-26 | 2021-07-06 | 海南海灵化学制药有限公司 | Synthesis process of latamoxef sodium |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103889425A (en) | TABLET INCLUDING 7-[4-(4-BENZO[b]THIOPHEN-4-YL-PIPERAZIN-1-YL) BUTOXY]-1H-QUINOLIN-2-ONE OR SALT THEREOF | |
| JP2003212852A (en) | Aripiprazole hydrate, aripiprazole anhydride crystal, preparation thereof and medicinal preparation containing the same | |
| CN109350611A (en) | The NMN nanosphere and its preparation process of cladding konjak glucomannan and application | |
| CN105193763B (en) | A kind of hydrobromic acid Vortioxetine piece and preparation method thereof | |
| CN106389374A (en) | Pharmaceutical composition containing LCZ696 and preparation method of pharmaceutical composition | |
| CN102218050A (en) | Pharmaceutical composition for treating depression | |
| US9586904B2 (en) | Preparation of (−)-huperzine A | |
| CN105878197A (en) | Riociguat orally disintegrating tablet and preparation method thereof | |
| CN103524533B (en) | A kind of cefprozil compound, its dispersible tablet, dry suspensoid and preparation method | |
| CN108815130A (en) | A kind of Cefpodoxime Proxetil tablet and its production technology | |
| CN107375247B (en) | Tilmicosin film-controlled enteric sustained-release preparation and preparation method thereof | |
| CN102327244A (en) | Ambroxol hydrochloride orally disintegrating tablet and preparation method thereof | |
| JP7085527B2 (en) | Erythritol granules and their manufacturing methods, as well as tablet manufacturing methods and tablets using them. | |
| CN102357093A (en) | Medicinal composition of methanesulfonic acid arbidol oral solid preparation | |
| CN106943356B (en) | A kind of famciclovir sustained-release granule and preparation method thereof | |
| CN101429154B (en) | Anhydrous alvimopan and medicament composition thereof | |
| CN105566314A (en) | Tizanidine hydrochloride compound | |
| CN102552198B (en) | Cefcapene pivoxil hydrochloride hydrate composition tablets | |
| CN107080741A (en) | Pirfenidone sustained release preparation and preparation method | |
| CN102671200B (en) | Isomaltose hypgather tablet excipient, medicine tablet and preparation method | |
| CN103446070B (en) | A kind of roflumilast solid immediate release preparation and preparation method thereof | |
| CN107569473B (en) | Ambroxol hydrochloride sustained-release capsule and preparation method thereof | |
| AU2021102577A4 (en) | Biopolymer nanosphere containing nicotinamide mononucleotide, preparation method therefor and use thereof | |
| JP2001213890A (en) | Trehalose particle | |
| CN109498578A (en) | Stable Olanzapine composition and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181116 |